Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study

Full metadata record
DC Field Value Language
dc.contributor.authorAh, Young-Mi-
dc.contributor.authorLee, Ju-Yeun-
dc.contributor.authorChoi, Yun-Jung-
dc.contributor.authorKong, Jisun-
dc.contributor.authorKim, Baegeum-
dc.contributor.authorChoi, Kyung Hee-
dc.contributor.authorHan, Nayoung-
dc.contributor.authorYu, Yun Mi-
dc.contributor.authorOh, Jung Mi-
dc.contributor.authorShin, Wan Gyoon-
dc.contributor.authorLee, Hae-Young-
dc.date.accessioned2022-07-15T18:02:38Z-
dc.date.available2022-07-15T18:02:38Z-
dc.date.issued2016-04-
dc.identifier.issn1064-1963-
dc.identifier.issn1525-6006-
dc.identifier.urihttps://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/154900-
dc.description.abstractWe identified 55 504 uncomplicated, treatment-naive hypertensive patients who started angiotensin II receptor blockers (ARBs) in 2012 from national claims data. The proportion of patients remaining on any hypertension treatment at 12 months and the adherence rate were similar between the losartan cohort (66.82% and 68.25%) and the nonlosartan ARB cohort (67.48% and 69.01%). After adjusting for confounding factors, there was no difference in persistence (aHR 0.98, 95% confidence interval (CI) 0.95-1.01) on hypertension treatment between losartan and nonlosartan ARB cohort. Post hoc analysis showed that patients initially prescribed eprosartan, irbesartan (both, aHR 1.33), and telmisartan (aHR 1.11) were more likely to discontinue the initial drug, whereas valsartan initiators (aHR 0.96) were less likely compared with losartan initiators.-
dc.format.extent6-
dc.language영어-
dc.language.isoENG-
dc.publisherMarcel Dekker Inc.-
dc.titleInfluence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study-
dc.typeArticle-
dc.publisher.location미국-
dc.identifier.doi10.3109/10641963.2015.1116548-
dc.identifier.scopusid2-s2.0-84961878141-
dc.identifier.wosid000373942800010-
dc.identifier.bibliographicCitationClinical and Experimental Hypertension, v.38, no.3, pp 325 - 330-
dc.citation.titleClinical and Experimental Hypertension-
dc.citation.volume38-
dc.citation.number3-
dc.citation.startPage325-
dc.citation.endPage330-
dc.type.docTypeArticle-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.relation.journalResearchAreaCardiovascular System & Cardiology-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalWebOfScienceCategoryPeripheral Vascular Disease-
dc.subject.keywordPlusMEDICATION ADHERENCE-
dc.subject.keywordPlusANTIHYPERTENSIVE MEDICATIONS-
dc.subject.keywordPlusRETROSPECTIVE COHORT-
dc.subject.keywordPlusDRUG CLASS-
dc.subject.keywordPlusIMPACT-
dc.subject.keywordPlusMETAANALYSIS-
dc.subject.keywordPlusPREVALENCE-
dc.subject.keywordPlusTRENDS-
dc.subject.keywordPlusDISCONTINUATION-
dc.subject.keywordPlusLOSARTAN-
dc.subject.keywordAuthorlosartan-
dc.subject.keywordAuthorhypertension-
dc.subject.keywordAuthorpersistence-
dc.subject.keywordAuthorangiotensin-receptor blocker-
dc.subject.keywordAuthorAdherence-
dc.identifier.urlhttps://www.tandfonline.com/doi/full/10.3109/10641963.2015.1116548-
Files in This Item
Go to Link
Appears in
Collections
서울 의과대학 > 서울 교육협력지원교실 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE